Skip to main content
. 2022 Sep;192(9):1282–1294. doi: 10.1016/j.ajpath.2022.05.006

Table 3.

Severe Disease in Non–COVID-19 Control Patients

Code Sex Age, y Primary Diagnoses Outcome Co-morbidities/thrombotic complications Fibrinogen, mg/dL AKI/dialysis AST, U/L ANC, /mm3 LDH, U/L
1 M 65 CMMoL, ARDS Discharged Allogeneic stem cell transplant, AIHA, CMV viremia, parainfluenza pneumonia 310 154 2.9 375
2 F 37 HELLP syndrome Discharged C-section
Gestational diabetes
176 +/No 266 16.7 513
3 F 38 ARDS Discharged Pneumonia, seizures ND +/No 108 15.2 1574
4 F 56 AML, ARDS Died Allogeneic stem cell transplant, cardiogenic shock, pneumonia, coronavirus infection (not CoV-1,2), DVT, PE 391 +/Yes 88 14.3 977
5 F 81 IgGκ multiple myeloma, ARDS Died DM2, pancreatitis, atrial fibrillation, influenza A pneumonia 525 +/No 94 11.0 1555
6 F 45 Angioimmunoblastic T-cell lymphoma Died Allogeneic stem cell transplant, Pseudomonas aeruginosa sepsis, HHV6 viremia, Coombs-negative hemolytic anemia, GvHD ND +/Yes 33 2.0 1549
7 F 72 r/o TTP Discharged HTN, HLD, atrial fibrillation/ischemic stroke ND 52 5.1 ND
8 M 76 Cryptogenic cirrhosis Discharged Coombs-negative hemolytic anemia ND 87 1.6 1479
9 M 86 Non-Hodgkin lymphoma, recurrent Died Sepsis, Coombs-negative hemolytic anemia 311 +/No 264 0.3 2751

F, female; M, male; +, presence of acute kidney injury (AKI); –, absence of AKI; AIHA, autoimmune hemolytic anemia; AML, acute myelogenous leukemia; ANC, absolute neutrophil count; ARDS, acute respiratory distress syndrome; AST, aspartate transaminase; CMMoL, chronic myelomonocytic leukemia; CMV, cytomegalovirus; CoV-1,2, coronavirus 1,2; COVID-19, coronavirus disease 2019; DM2, type 2 diabetes mellitus; DVT, deep vein thrombosis; GvHD, graft-versus-host disease; HELLP, hemolysis/elevated liver enzymes/low platelets; HHV6, human herpesvirus 6; HLD, hyperlipidemia; HTN, hypertension; LDH, lactate dehydrogenase; ND, not done; PE, pulmonary embolism; r/o, rule out; TTP, thrombotic thrombocytopenic purpura.